Platform Pipeline

About Syntiron

Syntiron is a private, preclinical-stage biotech company dedicated to developing bacterial vaccines to address the global crisis of antimicrobial resistance (AMR). Its proprietary ALLOY Vaccine Platform generates synthetic protein vaccines that target multiple bacterial iron receptors, aiming for strength, broad protection, and manufacturing simplicity. The company's lead program is a vaccine for urinary tract infections (UTI), a major driver of antibiotic use, and it has secured non-dilutive funding from CARB-X for a maternal vaccine to prevent neonatal sepsis. Syntiron operates as a small, focused team leveraging deep expertise in microbial genomics and structural biochemistry to advance its pipeline.

About Circurna

Circurna is a private, pre-clinical biotech leveraging a proprietary circular RNA (ciRNA™) platform to develop next-generation therapeutics. The platform is engineered to enable sustained protein expression, improved tolerability, room-temperature stable formulations, and flexible delivery methods like microneedle patches. With a pipeline spanning oncology, fibrosis, autoimmune, and infectious diseases, Circurna is positioning itself to address core limitations of first-generation RNA technologies and expand the reach of RNA medicine.

About aptaTargets

aptaTargets is a Spanish biotechnology company specializing in aptamer-based therapeutics for acute inflammatory conditions. Its lead asset, ApTOLL, a TLR4-targeting aptamer for acute ischemic stroke, has completed a positive Phase 1b/2a trial and received EMA PRIME designation. Following a strategic transfer of ApTOLL to Merck in 2024, aptaTargets is positioned to potentially advance its platform into other acute indications like myocardial infarction and multiple sclerosis.

About Frezent Biological Solutions

Frezent Biological Solutions is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel approach to oncology by developing therapeutics that target dormant cancer cells, a key driver of aggressive and treatment-resistant recurrence. Its pipeline consists of antibodies and ADCs aimed at preventing the reactivation of these cells, addressing a significant unmet need for over 30 million cancer survivors worldwide. Frezent is actively seeking partnerships and funding to advance its programs toward clinical development.

About Adicet Bio

Adicet Bio is developing first-in-class, allogeneic gamma delta T cell therapies designed to be safer, more readily available, and more effective in solid tumors and autoimmune diseases than current autologous CAR-T options. Its lead candidate, prula-cel (anti-CD20), is in Phase 1 development for B-cell mediated autoimmune diseases, with initial data showing a promising safety profile. The company's strategy hinges on validating its proprietary platform in autoimmune indications to derisk and fund expansion into the larger oncology market, leveraging the innate tissue-homing properties of its cell products.

Therapeutic Areas